Pharmaceutical Law & Industry Report® Index-Summary

VACCINES

– Gardasil for anal cancer prevention, 1634
– Prevnar 13 application, 44

VALCYTE

– Antiviral generic settlement (D.N.J.), 1142
– Transplant drug dosing recommendations, 1191

VERMONT

– Data mining law unconstitutional (2nd Cir.), 1496; (U.S., rev sought), 1614; BNA Insights, 1643
– Disclosure by drug firms, 656
– Marketing, drug firm spending, 465
– Rebates and drug assistance program, 789

VESANOID

– Leukemia drug withdrawal, 1191

VETERANS AFFAIRS (VA)

– Promotion of drugs, 597

VIAGRA

– Patents

– – Brazilian patent expiration, 604
– – Canadian patent suit (Fed. Ct.), 830; patent upheld (Fed. Ct. App.), 1327
– – Generic patent infringement claim (E.D. Va.), 454

– Stroke blamed on drug (E.D. La.), 626

VIDEX

– Approval, 531
– HIV drug and liver disorder, 171

VIGAMOX

– Eye drug generic stayed (D. Del.), 1053

VIOXX

– Australia, pain drug not fit for purpose, 372
– La. redhibition claim dismissal (E.D. La.), 889
– Master settlement agreement challenge (5th Cir.), 983
– Purchasers suit, no class certification (Cal. Ct. App.), 13; denial upheld (Cal.), 457
– Shareholders' securities fraud suit (U.S.), 554

VIRGINIA

– Consumer protection law and drug (W.Va.), 1619

VIVITROL

– Alcohol dependence treatment labeling, 600
– Application, 532; priority review, 730
– Approval recommended for opiod dependence, 1231; approved, 1323
– Welcome kit at issue, 1475

VPRIV

– Gaucher disease drug approval, 293

VYTORIN

– Bifurcation of patent (D.N.J.), 780
– Cancer link, 21
– Cholesterol drug, generic

– – Impax application (D.N.J.), 1107
– – Mylan ANDA (D.N.J.), 7

VYVANSE

– ADHD drug exclusivity decision challenge (D.D.C.), 311; exclusivity upheld (D.C. Cir.), 1425
– Approval, 1476